Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Kazia Therapeutics ( (KZIA) ) is now available.
On December 2, 2025, Kazia Therapeutics announced a $50 million private placement of equity securities with institutional and accredited investors, expected to close by December 3, 2025. The net proceeds of approximately $46.5 million will be used to further clinical development of their lead program, paxalisib, and other corporate purposes, extending the company’s cash runway into the second half of 2028. This strategic financial move is set to bolster Kazia’s position in the oncology drug development sector, supporting its ongoing trials and potential market expansion.
The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an innovative oncology-focused drug development company based in Sydney, Australia. The company is primarily engaged in the development of cancer treatments, with its lead program being paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor aimed at treating various forms of brain cancer, including glioblastoma and brain metastases. Additionally, Kazia is advancing EVT801, a selective VEGFR3 inhibitor, in a Phase 1 clinical trial for advanced solid tumors.
Average Trading Volume: 711,342
Technical Sentiment Signal: Sell
Current Market Cap: $15.29M
Find detailed analytics on KZIA stock on TipRanks’ Stock Analysis page.